Opportunity Information: Apply for W81XWH 15 PRARP CSRA
Apply for W81XWH 15 PRARP CSRA
- The Dept. of the Army USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD FY15 Peer Reviewed Alzheimer s Convergence Science Research Award" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420 Military Medical Research and Development.
- This funding opportunity was created on Jul 20, 2015 and posted on Jul 20, 2015.
- Applicants must submit their applications by Nov 25, 2015. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $2,800,000.00 to eligible and selected applicants.
- The number of recipients for this funding is limited to 4 candidate(s).
- Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The DoD FY15 Peer Reviewed Alzheimer s Convergence Science Research Award (CSRA) is a funding opportunity under the Department of the Army, USAMRAA, within the Peer Reviewed Alzheimer s Research Program (PRARP). It is designed to accelerate research at the intersection of traumatic brain injury (TBI) and Alzheimer s disease (AD), with a clear emphasis on outcomes that matter for military Service members and Veterans, while also benefiting civilian populations. The CSRA mechanism was introduced in FY12, and by FY15 the program reported 92 applications received and 22 recommended for funding, signaling that it is competitive and aimed at projects with strong potential to move the field forward.
At its core, the FY15 CSRA is meant to support the creation of research resources, enabling tools, and novel research efforts that other researchers and health science practitioners can use. In practice, that can include things like new datasets, assays, biomarkers, analytical platforms, shared infrastructure, or other tangible outputs that reduce barriers in the TBI to AD research space. Preliminary data is encouraged but not required, which makes the award suitable both for established lines of work that are ready to scale and for well-justified, high-impact ideas that may be earlier stage but still feasible and compelling.
Eligibility is broad in terms of discipline and institutional type, with the opportunity described as unrestricted, but it places an important requirement on leadership and team capability. The Principal Investigator must be at or above the level of Assistant Professor (or equivalent), and applicants can come from any field or discipline, reflecting the program s interest in convergence science and cross-cutting approaches. At the same time, the application must show that the study team has experience in both TBI and AD research, meaning a strong proposal typically needs credible expertise on both sides of the problem, either within one lab or through well-integrated collaboration.
The announcement requires each application to address at least one of three overarching challenges that the program sees as limiting progress for military and Veteran communities. First is the paucity of research resources for examining how TBI relates to later AD, which can include gaps in cohorts, biospecimens, standardized measures, animal models, or harmonized data. Second is the paucity of clinical or epidemiological studies that can clarify the relationship between TBI and subsequent AD, pointing to a need for better-designed human studies, longitudinal follow-up, and improved characterization of risk, timing, and modifying factors. Third is the need for diagnostic technologies, tests, or devices capable of detecting progression toward AD following TBI, highlighting an interest in practical detection methods that can be validated and potentially translated to clinical or field settings.
Beyond meeting one or more overarching challenges, proposals are expected to align with at least one FY15 focus area, unless the applicant makes a strong case for a different approach. The listed focus areas include genomics, proteomics, and bioinformatics, particularly strategies that characterize neurological changes associated with TBI and later AD, including genetic, proteomic, or epigenetic work and related testing technologies. Another focus area is the pathology of Tau, supporting studies and technologies aimed at understanding Tau-related mechanisms shared between or linking TBI and AD. A third focus area emphasizes the roles of non-neuronal cells in TBI/AD pathogenesis, such as astrocytes and other cell types that may drive neurodegeneration after injury, with interest in studies, tests, devices, or technologies that can reveal these mechanisms. The final focus area is novel target identification through basic, non-human research that directly leads to identifying new therapeutic targets for developing investigational agents, reflecting a pipeline-building interest rather than late-stage drug testing.
A notable boundary in the FY15 CSRA is what it discourages: pharmacologic interventions that require investigational or FDA-approved drugs or medicines, whether in clinical or basic research. This signals that the program is prioritizing discovery, tools, diagnostics, resources, and target identification rather than drug trials or studies that hinge on administering medications. Applicants proposing work outside the focus areas can still be considered, but they are expected to justify why their approach is the right fit for the program s mission and challenges.
From an administrative standpoint, this opportunity was posted July 20, 2015, with an original and current closing date of November 25, 2015, and an archive date of December 25, 2015. The anticipated funding level was about $2.8 million total, with an expected four awards, and no cost sharing or matching required. The funding instrument types listed include cooperative agreement and grant, under the Science and Technology and other Research and Development activity category, and it is associated with CFDA 12.420 (Military Medical Research and Development). For access issues or submission system support, the announcement points applicants to the CDMRP Help Desk (help@eBRAP.org, 301-682-5507).
FAQs: DoD FY15 Peer Reviewed Alzheimer's Convergence Science Research Award (CSRA)
What is the DoD FY15 Peer Reviewed Alzheimer's Convergence Science Research Award (CSRA)?
The CSRA is a funding opportunity within the Department of the Army, USAMRAA, under the Peer Reviewed Alzheimer's Research Program (PRARP). It is intended to accelerate research where traumatic brain injury (TBI) and Alzheimer's disease (AD) intersect, with a focus on outcomes that matter for military Service members and Veterans, while also benefiting civilian populations.
What is the main purpose of this award mechanism?
The FY15 CSRA is designed to support the creation of research resources, enabling tools, and novel research efforts that other researchers and health science practitioners can use. Examples described include datasets, assays, biomarkers, analytical platforms, shared infrastructure, and other tangible outputs that reduce barriers in TBI-to-AD research.
Who is administering this opportunity?
The opportunity is under the Department of the Army, USAMRAA, within the Peer Reviewed Alzheimer's Research Program (PRARP).
Who is the intended beneficiary population?
The program emphasizes outcomes relevant to military Service members and Veterans, while also aiming to generate benefits for civilian populations.
How competitive is the CSRA?
The FY15 program information notes that 92 applications were received and 22 were recommended for funding, indicating that the mechanism is competitive.
Is preliminary data required to apply?
No. Preliminary data is encouraged but not required, making the award suitable for both established efforts ready to scale and earlier-stage ideas that are well-justified, feasible, and compelling.
What kinds of project outputs does the CSRA emphasize?
The opportunity emphasizes outputs that can be broadly used by others, such as new or improved research resources, tools, datasets, assays, biomarkers, analytical platforms, shared infrastructure, and other enabling capabilities in the TBI-to-AD space.
What are the eligibility requirements for the Principal Investigator (PI)?
The PI must be at or above the level of Assistant Professor (or equivalent).
Are certain disciplines or institution types required or excluded?
Eligibility is described as broad and unrestricted in terms of discipline and institutional type, reflecting an emphasis on convergence science and cross-cutting approaches.
Does the research team need specific subject-matter experience?
Yes. The application must demonstrate that the study team has experience in both TBI and AD research. Strong proposals typically show credible expertise on both sides, either within one group or through well-integrated collaboration.
What overarching challenges must an application address?
Each application is required to address at least one of three overarching challenges identified by the program as limiting progress for military and Veteran communities.
What is the first overarching challenge described in the announcement?
The first challenge is the paucity of research resources for examining how TBI relates to later AD. This can include gaps in cohorts, biospecimens, standardized measures, animal models, or harmonized data.
What is the second overarching challenge?
The second challenge is the paucity of clinical or epidemiological studies that clarify the relationship between TBI and subsequent AD, including needs for better-designed human studies, longitudinal follow-up, and improved characterization of risk, timing, and modifying factors.
What is the third overarching challenge?
The third challenge is the need for diagnostic technologies, tests, or devices capable of detecting progression toward AD following TBI, with interest in practical detection methods that can be validated and potentially translated to clinical or field settings.
Do proposals need to fit within specific FY15 focus areas?
Proposals are expected to align with at least one FY15 focus area unless the applicant makes a strong case for a different approach and explains why it fits the program mission and challenges.
What FY15 focus area topics are specifically listed?
The listed FY15 focus areas include: (1) genomics, proteomics, and bioinformatics approaches characterizing neurological changes associated with TBI and later AD (including genetic, proteomic, or epigenetic work and related testing technologies); (2) pathology of Tau; (3) roles of non-neuronal cells (such as astrocytes) in TBI/AD pathogenesis, including studies, tests, devices, or technologies; and (4) novel target identification via basic, non-human research that directly leads to new therapeutic targets for developing investigational agents.
What does the focus area on genomics, proteomics, and bioinformatics emphasize?
It emphasizes strategies that characterize neurological changes associated with TBI and later AD, including genetic, proteomic, or epigenetic studies and related testing technologies.
What does the focus area on Tau address?
It supports studies and technologies aimed at understanding Tau-related mechanisms that are shared between, or link, TBI and AD.
What does the non-neuronal cells focus area include?
It highlights interest in the roles of non-neuronal cells (including astrocytes and other cell types) in TBI/AD pathogenesis, and includes studies, tests, devices, or technologies that reveal relevant mechanisms.
What does the novel target identification focus area prioritize?
It prioritizes basic, non-human research that directly leads to identifying new therapeutic targets for developing investigational agents, reflecting a pipeline-building emphasis rather than late-stage testing.
Are pharmacologic intervention studies encouraged under this award?
No. The announcement discourages pharmacologic interventions that require investigational or FDA-approved drugs or medicines, whether in clinical or basic research, signaling a priority on discovery, tools, diagnostics, resources, and target identification rather than studies that hinge on administering medications.
Can projects outside the listed focus areas still be considered?
Yes. Applicants proposing work outside the focus areas can still be considered, but they are expected to justify why their approach is the right fit for the program mission and challenges.
When was this opportunity posted and when did it close?
The opportunity was posted on July 20, 2015. The original and current closing date was November 25, 2015. The archive date was December 25, 2015.
What was the anticipated total funding and expected number of awards?
The anticipated total funding level was about $2.8 million, with an expectation of four awards.
Is cost sharing or matching required?
No. The opportunity specifies that no cost sharing or matching is required.
What funding instrument types were listed for this opportunity?
The funding instrument types listed include a cooperative agreement and a grant.
What activity category is associated with this funding opportunity?
It is associated with the "Science and Technology and other Research and Development" activity category.
What CFDA number is associated with this opportunity?
The opportunity is associated with CFDA 12.420 (Military Medical Research and Development).
Who should applicants contact for access issues or submission system support?
The announcement directs applicants to the CDMRP Help Desk at help@eBRAP.org or 301-682-5507.
Browse more opportunities from the same category: Science and Technology and other Research and Development
Next opportunity: Longevity of Voluntary Conservation Actions
Previous opportunity: Yuma Crossing National Heritage Area Corporation FY2015 Implementation of Management Plan
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for W81XWH 15 PRARP CSRA
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (W81XWH 15 PRARP CSRA) also looked into and applied for these:
| Funding Opportunity |
|---|
| DoD Epilepsy Idea Development Award Apply for W81XWH 15 ERP IDA Funding Number: W81XWH 15 ERP IDA Agency: Dept. of the Army USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| HUMAN EXPLORATION RESEARCH OPPORTUNITIES NASA RESEARCH ANNOUNCEMENT Apply for NNJ15ZSA001N Funding Number: NNJ15ZSA001N Agency: NASA Johnson Space Center Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Collaborative Fusion Energy Research in the DIII D National Program Apply for DE FOA 0001375 Funding Number: DE FOA 0001375 Agency: Office of Science Category: Science and Technology and other Research and Development Funding Amount: $3,000,000 |
| ROSES 2015 Mars Data Analysis Program Apply for NNH15ZDA001N MDAP Funding Number: NNH15ZDA001N MDAP Agency: NASA Headquarters Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Engineering Research Centers Apply for 15 589 Funding Number: 15 589 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD FY15 Reconstructive Transplant Research (RTR) Concept Award Apply for W81XWH 15 RTR CA Funding Number: W81XWH 15 RTR CA Agency: Dept. of the Army USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD FY15 Reconstructive Transplant Research (RTR) Clinical Trial Award Apply for W81XWH 15 RTR CTA Funding Number: W81XWH 15 RTR CTA Agency: Dept. of the Army USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD FY15 Reconstructive Transplant Research (RTR) Idea Discovery Award Apply for W81XWH 15 RTR IDA Funding Number: W81XWH 15 RTR IDA Agency: Dept. of the Army USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD FY15 Reconstructive Transplant Research (RTR) Translational Research Award Apply for W81XWH 15 RTR TRA Funding Number: W81XWH 15 RTR TRA Agency: Dept. of the Army USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Department of Defense Explosive Ordnance Disposal Science and Technology Apply for N00014 15 R SN13 Funding Number: N00014 15 R SN13 Agency: Office of Naval Research Category: Science and Technology and other Research and Development Funding Amount: $700,000 |
| DoD Breast Cancer Breakthrough Award Level 3 Award Apply for W81XWH 15 BCRP BREAKTHROUGH2 FL3 Funding Number: W81XWH 15 BCRP BREAKTHROUGH2 FL3 Agency: Dept. of the Army USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| FY15 Supplemental for Evaluation of Wheel/Rail Contact Mechanics, VT Apply for FR RRD 15 015 Funding Number: FR RRD 15 015 Agency: DOT/Federal Railroad Administration Category: Science and Technology and other Research and Development Funding Amount: $231,000 |
| CISE Research Infrastructure Apply for 15 590 Funding Number: 15 590 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $2,500,000 |
| Biotechnology and Biochemical Engineering Apply for PD 15 1491 Funding Number: PD 15 1491 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $600,000 |
| Nano Biosensing Apply for PD 15 7909 Funding Number: PD 15 7909 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $600,000 |
| Nano Bio Phenomena and Processes in the Environment Apply for PD 15 1179 Funding Number: PD 15 1179 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Environmental Engineering Apply for PD 15 1440 Funding Number: PD 15 1440 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Fluid Dynamics Apply for PD 15 1443 Funding Number: PD 15 1443 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| General Age Related Disabilities Engineering Apply for PD 15 5342 Funding Number: PD 15 5342 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Biomedical Engineering Apply for PD 15 5345 Funding Number: PD 15 5345 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $600,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "W81XWH 15 PRARP CSRA", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.